FDA rejects cancer therapy for rare post-transplant disease / Beckers

Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

---

Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 7 wks

Related Stories

---

• FDA launches individualized therapy framework for ultra-rare diseases / 14 days
• FDA makes one pivotal trial the default for drug approvals / 20 days
• FDA refuses to review Moderna mRNA flu vaccine application / 28 days
• Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 11 days
• World Cancer Day Global Awareness Campaign / 4 wks
• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
• FDA Abortion Pill Decisions Rooted in Science / 7 wks

Related Tags

---

StackHealth Time Machine

---